

Prescribing Clinical Network

Policy Statement	Ustekinumab for treating active psoriatic arthritis
Policy No:	PCN 167-2015
Date of Issue	September - 2015
Review Date:	September -2018 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
Recommendations: The PCN recommends Ustekinumab as a treatment option for treating active Psoriatic Arthritis in adults in line with NICE TA340.	
Key Considerations: <ul style="list-style-type: none"> NICE TA 340 https://www.nice.org.uk/guidance/ta340/resources/ustekinumab-for-treating-active-psoriatic-arthritis-rapid-review-of-technology-appraisal-guidance-313-82602601123525 The Psoriatic Arthritis Pathway has been updated to include Ustekinumab as a treatment option <p>Post PCN meeting note: (December 2016) The PCN should be aware that the consequence of the publication of this NICE TA is that there is a cohort of patients who will have received all the lines of biologic treatment in the pathway but will now be eligible for treatment with Ustekinumab as per the NICE TA.</p>	
Date taken to Prescribing Clinical Network	Virtual decision September 2015
Agreed by PCN members	December 2016

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG